Literature DB >> 25149396

Production and characterization of thirteen human type-I interferon-α subtypes.

Srilalitha Kuruganti1, Mary Ann Accavitti-Loper1, Mark R Walter2.   

Abstract

Thirteen human interferon-α (IFNα) subtypes were expressed in Escherichiacoli and purified using an N-terminal affinity tag from the prodomain of subtilisin. IFNα subtypes were expressed in soluble form and purified from cell lysates or refolded and purified from inclusion bodies. Proteins produced by either protocol exhibited biological activities equal to or greater than commercially prepared IFNα preparations. The IFNαs were used to produce an anti-IFNα16 antibody (MAb-1B12) that specifically neutralized the biological activity of IFNα16, but not the 12 other IFNαs. Using MAb-1B12, and a previously generated IFNAR1/IFNAR2-FChk heterodimer, an assay was developed to determine total type I IFN biological activity and IFNα16-derived biological activity in an unknown sample.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune disease; Interferon; Interferon subtype; Neutralizing antibodies; Protein purification

Mesh:

Substances:

Year:  2014        PMID: 25149396      PMCID: PMC4466898          DOI: 10.1016/j.pep.2014.08.010

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  39 in total

1.  High yield expression, refolding, and characterization of recombinant interferon alpha2/alpha8 hybrids in Escherichia coli.

Authors:  Dimitris Platis; Graham R Foster
Journal:  Protein Expr Purif       Date:  2003-10       Impact factor: 1.650

2.  Structural insights into a human anti-IFN antibody exerting therapeutic potential for systemic lupus erythematosus.

Authors:  Songying Ouyang; Bin Gong; Jin-Zhi Li; Li-Xia Zhao; Wei Wu; Fu-Shun Zhang; Lina Sun; Shu-Jun Wang; Meng Pan; Chuan Li; Wenguang Liang; Neil Shaw; Jie Zheng; Guo-Ping Zhao; Ying Wang; Zhi-Jie Liu; Mifang Liang
Journal:  J Mol Med (Berl)       Date:  2012-02-04       Impact factor: 4.599

3.  Re-treatment with highly purified nIFNα in Mexican nonresponder patients with chronic genotype 1 hepatitis C.

Authors:  Linda E Muñoz-Espinosa; Paula Cordero-Pérez; Eduardo Marín-López; Liliana Torres-González; Rene Malé-Velázquez; Rolando Armienta-Sarabia; María Elena Hernández-Gómez; José de Jesús Ernesto Núñez-Camarena; Marco Antonio Olivera-Martínez; Juan Francisco Sánchez-Avila
Journal:  Arch Med Res       Date:  2013-09-17       Impact factor: 2.235

4.  Distinct antiviral activities of IFN-α subtypes.

Authors:  Kathrin Gibbert; Ulf Dittmer
Journal:  Immunotherapy       Date:  2011-07       Impact factor: 4.196

5.  Establishment of new and replacement World Health Organization International Biological Standards for human interferon alpha and omega.

Authors:  A Meager; R Gaines Das; K Zoon; A Mire-Sluis
Journal:  J Immunol Methods       Date:  2001-11-01       Impact factor: 2.303

Review 6.  Lupus neutrophils: 'NET' gain in understanding lupus pathogenesis.

Authors:  Jason S Knight; Mariana J Kaplan
Journal:  Curr Opin Rheumatol       Date:  2012-09       Impact factor: 5.006

Review 7.  The type I interferon system in the development of lupus.

Authors:  Lars Rönnblom; Gunnar V Alm; Maija-Leena Eloranta
Journal:  Semin Immunol       Date:  2011-02-02       Impact factor: 11.130

Review 8.  Immunomodulatory functions of type I interferons.

Authors:  José M González-Navajas; Jongdae Lee; Michael David; Eyal Raz
Journal:  Nat Rev Immunol       Date:  2012-01-06       Impact factor: 53.106

9.  Purification and biological characterization of soluble, recombinant mouse IFNβ expressed in insect cells.

Authors:  Sebastian A Stifter; Jodee A Gould; Niamh E Mangan; Hugh H Reid; Jamie Rossjohn; Paul J Hertzog; Nicole A de Weerd
Journal:  Protein Expr Purif       Date:  2013-11-06       Impact factor: 1.650

10.  Kinetic analysis of cytokine-mediated receptor assembly using engineered FC heterodimers.

Authors:  Ashlesha Deshpande; Balananda-Dhurjati Kumar Putcha; Srilalitha Kuruganti; Mark R Walter
Journal:  Protein Sci       Date:  2013-06-06       Impact factor: 6.725

View more
  7 in total

1.  Cytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes.

Authors:  Srilalitha Kuruganti; Shane Miersch; Ashlesha Deshpande; Jeffrey A Speir; Bethany D Harris; Jill M Schriewer; R Mark L Buller; Sachdev S Sidhu; Mark R Walter
Journal:  J Biol Chem       Date:  2015-11-06       Impact factor: 5.157

2.  A panel of synthetic antibodies that selectively recognize and antagonize members of the interferon alpha family.

Authors:  S Miersch; S Kuruganti; M R Walter; S S Sidhu
Journal:  Protein Eng Des Sel       Date:  2017-09-01       Impact factor: 1.650

3.  Human interferon-ϵ and interferon-κ exhibit low potency and low affinity for cell-surface IFNAR and the poxvirus antagonist B18R.

Authors:  Bethany D Harris; Jessica Schreiter; Marc Chevrier; Jarrat L Jordan; Mark R Walter
Journal:  J Biol Chem       Date:  2018-08-31       Impact factor: 5.157

4.  Characterization of Type-I IFN subtype autoantibodies and activity in SLE serum and urine.

Authors:  Bethany D Harris; Srilalitha Kuruganti; Ashlesha Deshpande; Paul A Goepfert; W Winn Chatham; Mark R Walter
Journal:  Lupus       Date:  2020-07-01       Impact factor: 2.911

5.  Cloning, expression and antiviral activity of mink alpha-interferons.

Authors:  Hai-ling Zhang; Jian-jun Zhao; Xiu-li Chai; Lei Zhang; Xue Bai; Bo Hu; Hao Liu; Dong-liang Zhang; Ming Ye; Wei Wu; Xi-jun Yan
Journal:  BMC Vet Res       Date:  2015-02-21       Impact factor: 2.741

6.  Electrostatically Driven Guanidinium Interaction Domains that Control Hydrogel-Mediated Protein Delivery In Vivo.

Authors:  Stephen E Miller; Yuji Yamada; Nimit Patel; Ernesto Suárez; Caroline Andrews; Steven Tau; Brian T Luke; Raul E Cachau; Joel P Schneider
Journal:  ACS Cent Sci       Date:  2019-10-18       Impact factor: 14.553

7.  Camelid type I interferons: Identification and functional characterization of interferon alpha from the dromedary camel (Camelus dromedarius).

Authors:  Avinash Premraj; Abi George Aleyas; Binita Nautiyal; Thaha Jamal Rasool
Journal:  Mol Immunol       Date:  2020-01-31       Impact factor: 4.407

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.